3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Epstein-Barr Virus Infections
1
Colorectal Neoplasms
1
Interventions
fludarabine
52
Cyclophosphamide
50
venetoclax
47
Azacitidine
44
fludarabine phosphate
41
Whole-Body Irradiation
33
Specimen Handling
31
Mycophenolic Acid
30
Tacrolimus
28
Melphalan
28
Busulfan
27
Cytarabine
25
Stem Cell Transplantation
23
Decitabine
23
Biopsy
22
Granulocyte Colony-Stimulating Factor
19
Sirolimus
16
Peripheral Blood Stem Cell Transplantation
16
Filgrastim
16
Thiotepa
15
decitabine and cedazuridine drug combination
14
Injections
13
Cyclosporine
13
ruxolitinib
9
Methotrexate
9
Mesna
9
Hematopoietic Stem Cell Transplantation
9
X-Rays
8
Idarubicin
8
Daunorubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
AP 1903 reagent
×
1 year
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled